Semaglutide in Litauen, online
Ein in der EU zugelassener Arzt prüft Ihren Fall und stellt, wenn es passt, ein E-Rezept aus, das Sie in einer Apotheke in Litauen einlösen.
Preis der Beratung. Das Medikament zahlen Sie in Ihrer Apotheke.
- Nur auf Rezept, wenn eine Ärztin oder ein Arzt zustimmt
- Ärztlich geprüfte Folgerezepte
- Volle Rückerstattung bei Ablehnung
Zugelassene Ärztinnen und Ärzte in der EU
Jeder Fall wird von einer zugelassenen Ärztin oder einem zugelassenen Arzt gelesen.
Antwort in unter 2 Stunden
Im Durchschnitt, schriftlich, kein Videoanruf.
Zahlung nur bei Zustimmung
Nicht genehmigt? Vollständige Erstattung, automatisch.
Auf Trustpilot als hervorragend bewertet
4.8 aus 540+ unabhängigen Bewertungen.
In der gesamten EU gültig
E-Rezept in Apotheken in der EU anerkannt.
Semaglutide-Beratungen in Litauen
Was es ist und wie es wirkt
Semaglutide is a GLP-1 receptor agonist, a medication that mimics a natural hormone your gut releases after eating. It reduces appetite, slows gastric emptying and helps maintain sustained weight loss when combined with supervised nutrition and activity changes.
It's prescribed alongside changes to diet and activity, as part of a medically supervised plan, not on its own, and not as a shortcut. A licensed EU doctor decides whether it's appropriate and safe for you.
Für wen es ist
- Adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition.
- One injection under the skin, once a week, on the same day each week.
Sicherheit im Überblick
Nausea and vomiting are very common; severe stomach pain can signal pancreatitis.
Sicherheitsübersicht lesenEine Beratung, ein klarer Preis
Sie zahlen die ärztliche Beratung. Wird ein Rezept ausgestellt, zahlen Sie das Medikament in Ihrer eigenen Apotheke.
- Beratung, geprüft von einem in der EU zugelassenen Arzt
- Private Nachbetreuung im Chat der App
- Volle Erstattung, wenn der Arzt nicht zustimmt
Gewichtsverlust
- Erstkonsultation inklusive
- Verlängerungen von deinem Arzt geprüft
- Laufende Betreuung in deinem privaten Chat
- Jederzeit kündbar
Volle Rückerstattung, wenn eine Prüfung nicht genehmigt wird
Ihre Fragen, beantwortet
Was ist Semaglutid und wie unterstützt es das Gewichtsmanagement?
Wer kommt für eine Behandlung mit Semaglutid infrage?
Weitere Fragen
Was sind die häufigsten Nebenwirkungen?
Wie lange dauert es, bis es wirkt, und wie wird es überwacht?
Was passiert, wenn ich Semaglutid absetze?
Wie lange dauert es, bis Semaglutid wirkt?
Darf ich während der Behandlung mit Semaglutid Alkohol trinken?
Was sollte ich tun, wenn unter Semaglutide Nebenwirkungen auftreten?
Kann ich Semaglutide zusammen mit meinen anderen Medikamenten anwenden?
Welche Alternativen gibt es, wenn Semaglutide nicht das Richtige für mich ist?
Wie läuft die Nachsorge ab, während ich Semaglutide anwende?
Kann ich aus Litauen eine Beratung zu Semaglutide erhalten?
Wer kommt für ein ärztlich begleitetes Programm zum Gewichtsmanagement infrage?
Was ist das private elektronische Rezept und warum ist es in der gesamten EU gültig?
Wie funktioniert Hi-Doctor Schritt für Schritt?
Was kostet es und was ist im Preis enthalten?
Wie Ihr Arzt entscheidet
Ihre Antworten
Ein approbierter Arzt liest Ihren gesamten Fragebogen.
Ärztliches Urteil
Die Entscheidung ist medizinisch, nie ein Algorithmus.
Ein klares Ergebnis
Genehmigt mit E-Rezept oder vollständig erstattet.
Verwandte Medikamente
Arzneimittelinformationen und Sicherheit
Wie wirkt Semaglutide?
It copies a natural gut hormone. Semaglutide is a close copy of GLP-1, a hormone your gut releases after you eat. It shares about 94% of the structure of the natural hormone, so it fits the same docking points on cells, but it is built to last much longer in the body.
It acts on appetite centres. Once attached to those docking points, semaglutide signals the parts of the brain that control hunger, including the hypothalamus and brainstem. In clinical studies people reported feeling full sooner, staying full for longer, feeling less hungry, and having fewer and weaker food cravings.
Eating less drives the change. Because appetite falls, most people take in fewer calories without consciously trying, and that gap is what produces weight change over months. Semaglutide also slightly slows how fast the stomach empties early after a meal, and prompts insulin release only when blood sugar is high.
Anwendung von Semaglutide
One injection, same day weekly. Semaglutide for weight management is injected under the skin once a week, at any time of day, with or without food. Most people pick a fixed day and set a reminder, because the weekly rhythm is easy to lose track of.
Choose and rotate injection sites. The approved sites are the abdomen, the thigh and the upper arm. The site can be changed from week to week. Rotating between sites is standard practice for injections under the skin and helps avoid repeated irritation in one spot.
Use a fresh needle every time. Attach a new needle for each injection and remove it afterwards, storing the pen without a needle attached. The product information says this helps prevent blocked needles, contamination, infection, leaking solution and inaccurate dosing. Compatible needles are 30G, 31G or 32G.
Check the liquid before injecting. Look at the solution first. It should be clear and colourless. The product information says not to use the pen if the liquid looks otherwise, or if it has been frozen at any point. Pens must never be shared between people.
Follow the pack instructions exactly. Each pen type has its own instructions for use inside the carton, and the product information asks patients to read them carefully before the first injection. With a single-dose pen you press it firmly against the skin until the yellow bar stops moving.
If you miss a dose. Take a missed dose as soon as possible, as long as fewer than five days have passed. If more than five days have gone by, skip it and take the next dose on the normal day. Ask the prescriber before restarting after several missed doses.
Moving your weekly dosing day. The day of the week can be changed if needed, provided at least three days, meaning more than 72 hours, separate one dose from the next. After moving to a new day, carry on with the once-weekly pattern from there.
Storing the pen correctly. Before first use, keep the pen in the fridge between 2°C and 8°C, away from the cooling element, and never freeze it. Keep the cap on to protect it from light. After first use a FlexTouch pen keeps for six weeks below 30°C.
Häufige Nebenwirkungen
Stop and get urgent medical help if (seek medical help immediately): Severe, persistent stomach pain, often spreading through to the back, Sudden loss of vision, including partial loss in one eye, Swelling of the face, lips, tongue or throat, or trouble breathing, Severe stomach pain with bloating, vomiting and no bowel movements, Pain under the right ribs with fever or yellowing skin, Vomiting or diarrhoea so severe that you cannot keep fluids down, Shakiness, confusion or sweating if you also take insulin or a sulfonylurea
Very common (very common (≥1/10)): Feeling sick (nausea), Being sick (vomiting), Diarrhoea, Constipation, Stomach pain, Headache, Tiredness
Common (common (≥1/100 to <1/10)): Dizziness, Altered sense of taste, Unusual skin sensations such as tingling or numbness, Indigestion, heartburn or acid reflux, Inflammation of the stomach lining (gastritis), Burping, wind or a bloated stomach, Gallstones, Hair loss, Reactions where the injection was given, Low blood sugar, in people who also have type 2 diabetes, Worsening of diabetic eye disease, in people with type 2 diabetes
Uncommon (uncommon (≥1/1,000 to <1/100)): Inflammation of the pancreas (acute pancreatitis), The stomach emptying more slowly than usual, A faster heart rate, Low blood pressure, Feeling dizzy on standing up (orthostatic hypotension), Raised amylase and lipase, two pancreatic enzymes, in blood tests
Rare (rare (≥1/10,000 to <1/1,000)): Severe allergic reaction affecting the whole body (anaphylaxis), Swelling of the face, lips, tongue or throat (angioedema)
Very rare (very rare (<1/10,000)): Sudden loss of vision caused by damage to the optic nerve
Reported, frequency not known (frequency not known): Blockage of the bowel (intestinal obstruction)
Nehmen Sie Semaglutide nicht ein, wenn
- You have ever had an allergic reaction to semaglutide or any ingredient in the pen
- You are pregnant, planning a pregnancy within the next two months, or breastfeeding
- You have type 1 diabetes, because semaglutide is not a substitute for insulin
- You already take another GLP-1 receptor agonist, as the combination has not been evaluated
- You take another prescription weight-management medicine at the same time
- You have severe kidney impairment, including end-stage kidney disease
- You have severe liver impairment
- You have severe gastroparesis, a condition where the stomach empties very slowly
- You have congestive heart failure classed as New York Heart Association class IV
- You have type 2 diabetes with uncontrolled or unstable diabetic eye disease
Arzneimittel und Substanzen mit Wechselwirkungen
- Warfarin and other coumarin blood thinners: Cases of a reduced INR clotting measure have been reported alongside semaglutide. Prescriber arranges more frequent INR blood tests when semaglutide is started.
- Insulin: Combined with semaglutide in type 2 diabetes, the risk of low blood sugar rises. Prescriber may lower the insulin dose at the start and monitor blood sugar.
- Sulfonylureas (e.g. gliclazide): Also raise the risk of low blood sugar when taken alongside semaglutide. Prescriber may reduce the sulfonylurea dose when semaglutide is introduced.
- Oral medicines needing fast absorption: Semaglutide slows stomach emptying, which could in principle affect how they are absorbed. Prescriber uses caution and reviews whether timing or monitoring needs changing.
- Combined oral contraceptives: No clinically relevant change; levonorgestrel exposure rose 20%, ethinylestradiol was unaffected. No dose change needed. Contraception is advised while taking semaglutide.
- Paracetamol: Peak levels fell 23% with semaglutide 1 mg, but total exposure was unchanged. No dose adjustment of paracetamol is required.
- Atorvastatin: Peak level fell 38% but overall exposure was unchanged, judged not clinically relevant. No dose adjustment is required.
- Digoxin and metformin: Semaglutide did not change overall exposure or peak levels of either medicine. No dose adjustment is required.
Quellen
- Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
- Wegovy: Annex I Summary of Product Characteristics (EU product information) European Medicines Agency, 2026
- Wegovy (semaglutide): European Public Assessment Report overview European Medicines Agency, 2026
- Ozempic (semaglutide) solution for injection: Summary of Product Characteristics, type 2 diabetes indication electronic medicines compendium (emc), 2026
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine (Wilding JPH et al., 384:989-1002), 2021
- STEP 4: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance JAMA (Rubino D et al., 325:1414-1425), 2021
- SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine (Lincoff AM et al., 389:2221-2232), 2023
- Semaglutide (Wegovy, Ozempic, Rybelsus): NHS medicines A to Z National Health Service (UK), 2026
- Wegovy FlexTouch: authorisation and supply classification record AEMPS CIMA (Spain), 2026
- Ficha técnica Wegovy 2,4 mg FlexTouch: EU Summary of Product Characteristics, section 4.8 adverse reaction table AEMPS CIMA (Spain), 2026
- Situación de financiación de medicamentos: Wegovy 2,4 mg, national code 758089 Ministerio de Sanidad (Spain), 2023
- G-BA implements the statutory prescribing exclusion for the weight-loss medicine Wegovy Gemeinsamer Bundesausschuss (Germany), 2024
- Obésité: de nouveaux médicaments peuvent être pris en charge dans des conditions encadrées Assurance Maladie / ameli.fr (France), 2026
- Wegovy niet vergoeden uit het basispakket: GVS advice on semaglutide for obesity Zorginstituut Nederland, 2024
- Medicines to treat obesity: reimbursement status of semaglutide in Ireland Health Service Executive (Ireland), 2026
- Obwieszczenie Ministra Zdrowia: wykaz refundowanych leków (pharmacy reimbursement list) Ministerstwo Zdrowia (Poland), 2026
- Rejestr Produktów Leczniczych: Wegovy (semaglutidum) registration record, ATC A10BJ06 Rejestry Medyczne / e-Zdrowie (Poland), 2026
- Behandlungspfad Übergewicht & Adipositas: case-by-case consideration of weight-reduction medicines Dachverband der österreichischen Sozialversicherung (Austria), 2026
- Warning on falsified GLP-1 receptor agonists: prescription status and pharmacy-only supply in Austria Bundesamt für Sicherheit im Gesundheitswesen (BASG, Austria), 2026
- Nieuwigheden geneesmiddelen: Wegovy commercialised in Belgium, not reimbursed for obesity Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI/CBIP), 2025
- Wegovy FlexTouch: INFARMED market authorisation notice and semaglutide safety communication INFARMED, I.P. (Portugal), 2026
- Nuovi farmaci per il diabete e l'obesità: AIFA guide to responsible use, Wegovy class C classification Agenzia Italiana del Farmaco (AIFA), 2026
- Mounjaro (tirzepatide): European Public Assessment Report overview European Medicines Agency, 2026
- Saxenda (liraglutide): European Public Assessment Report overview European Medicines Agency, 2026
- Saxenda 6 mg/mL solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
- Xenical (orlistat): European Public Assessment Report overview European Medicines Agency, 2026
Auch verfügbar in
- Sevilla
- Málaga
- Córdoba
- Granada
- Jerez de la Frontera
- Almería
- Huelva
- Cádiz
- Jaén
- Marbella
- Zaragoza
- Huesca
- Teruel
- Oviedo
- Gijón
- Avilés
- Palma de Mallorca
- Ibiza
- Mahón
- Las Palmas de Gran Canaria
- Santa Cruz de Tenerife
- San Cristóbal de La Laguna
- Telde
- Arona
- Santander
- Toledo
- Valladolid
- Barcelona
- Valencia
- Alicante
- Mérida
- Vigo
- Santiago de Compostela
- Logroño
- Madrid
- Murcia
- Pamplona
- Bilbao
- Vitoria-Gasteiz
- San Sebastián
- Berlin
- Hamburg
- München
- Köln
- Frankfurt
- Stuttgart
- Düsseldorf
- Leipzig
- Dortmund
- Essen
- Paris
- Marseille
- Lyon
- Toulouse
- Nizza
- Nantes
- Montpellier
- Straßburg
- Bordeaux
- Lille
- Rom
- Mailand
- Neapel
- Turin
- Palermo
- Genua
- Bologna
- Florenz
- Bari
- Catania
- Warschau
- Krakau
- Łódź
- Breslau
- Poznań
- Danzig
- Szczecin
- Bydgoszcz
- Amsterdam
- Rotterdam
- Den Haag
- Utrecht
- Eindhoven
- Groningen
- Tilburg
- Almere
- Brüssel
- Antwerpen
- Gent
- Charleroi
- Lüttich
- Brügge
- Namur
- Lissabon
- Porto
- Vila Nova de Gaia
- Amadora
- Braga
- Coimbra
- Bukarest
- Cluj-Napoca
- Iași
- Timișoara
- Constanța
- Craiova
- Athen
- Thessaloniki
- Patras
- Piräus
- Prag
- Brno
- Ostrava
- Pilsen
- Budapest
- Debrecen
- Szeged
- Miskolc
- Wien
- Graz
- Linz
- Salzburg
- Stockholm
- Göteborg
- Malmö
- Uppsala
- Västerås
- Helsinki
- Espoo
- Tampere
- Vantaa
- Kopenhagen
- Aarhus
- Odense
- Aalborg
- Dublin
- Cork
- Limerick
- Galway
- Sofia
- Plovdiv
- Varna
- Burgas
- Bratislava
- Košice
- Prešov
- Žilina
- Zagreb
- Split
- Rijeka
- Osijek
- Vilnius
- Kaunas
- Klaipėda
- Šiauliai
- Panevėžys
- Ljubljana
- Maribor
- Celje
- Riga
- Daugavpils
- Liepāja
- Jelgava
- Tallinn
- Tartu
- Narva
- Nicosia
- Limassol
- Larnaca
- Paphos
- Luxemburg
- Esch-sur-Alzette
- Valletta
- Birkirkara
- Qormi
- Mosta
- Spanien
- Frankreich
- Deutschland
- Italien
- Portugal
- Niederlande
- Belgien
- Irland
- Polen
- Tschechien
- Slowakei
- Ungarn
- Rumänien
- Bulgarien
- Griechenland
- Zypern
- Kroatien
- Slowenien
- Österreich
- Dänemark
- Schweden
- Finnland
- Estland
- Lettland
- Luxemburg
- Malta
Beginnen Sie Ihre Behandlung
Eine Ärztin oder ein Arzt antwortet im Schnitt in unter 2 Stunden.
Beratung startenKeine Kosten, solange kein Arzt Ihre Behandlung freigibt.
Zahlen Sie nichts, wenn ein Arzt Ihre Behandlung nicht genehmigt. Jede Beratung ist vollständig erstattungsfähig. So funktionieren Rückerstattungen